White House pulls its FDA nominee a day before the Senate vote, leaving the agency with an acting chief
Heidi Overton's nomination was withdrawn Tuesday night, hours before a Senate committee vote. Sen. Roger Marshall is reportedly under consideration, and drugmakers face more months without a confirmed commissioner.
The Trump administration withdrew Heidi Overton's nomination to run the Food and Drug Administration on Tuesday evening, less than a day before the Senate health committee was due to vote on it. A White House official confirmed the withdrawal to MS NOW, which said Axios reported it first. The official gave no reason.
Why it fell apart, according to two accounts
Reuters, as summarized by Pharmaceutical Commerce, reported that three sources said she lacked enough support in Congress. Republicans hold a one-seat majority on the HELP committee, so a single defection could have stalled her. Reuters also said some officials grew doubtful after the party lost its House and Senate majorities in the midterms.
The committee chair, Sen. Bill Cassidy, gave a different explanation on X, according to MS NOW. He said Overton had a "viable confirmation path," and that the real obstacle was the White House's reluctance to meet demands from anti-abortion senators for tighter limits on abortion pills. The White House had not responded to MS NOW on that claim. Cassidy had also criticized her role in the August executive order on the childhood vaccine schedule and her lack of managerial experience.
What happens now
- Who runs the FDA: Kyle Diamantas, the deputy commissioner for food, continues as acting commissioner.
- Who is next: Reuters, per Pharmaceutical Commerce, said two sources named Sen. Roger Marshall of Kansas as under consideration. This is unconfirmed and the White House has named no one.
- History: Overton was nominated Aug. 19, three months after Marty Makary stepped down. Pharmaceutical Commerce reports she was the administration's third choice for the job.
Who it hits
The people watching hardest are small and mid-size drug developers with a filing or review date on the calendar. Reuters reported that more than 4,500 employees have left the FDA over the past year, and industry executives told Pharmaceutical Commerce that reversals under Makary disrupted the review timelines they plan around. Under Diamantas, the agency has reopened paths for rare-disease therapies from Regenxbio, uniQure and Replimune, according to the same outlet. Whether a new commissioner would keep that direction is the open question, and nobody on the record has answered it.
Seeking Alpha's headline listed Capricor and Regenxbio among gainers after the news. We could not read the article and have no price figures, so we do not state a move. For context, the biotech ETF XBI closed Nov. 17 at $145.28, 14.3% below its Aug. 19 high, per Yahoo Finance data.
The dates that matter
The FDA's safety review of mifepristone is the issue Cassidy pointed to. Pharmaceutical Commerce says the agency expects to finish it by March 2027, and that review will land under whoever leads the agency then. For a biotech with an approval decision before that, the practical point is simple: the person signing off is currently an acting official, and a confirmation fight, if one comes, will not finish quickly. Companies cannot do anything about that except plan their timelines around the review calendar they already have.
For related coverage of how federal agencies are handling pressure right now, see our US news section and the stocks desk.
Sources: MS NOW; Pharmaceutical Commerce (citing Reuters); Seeking Alpha headline; Yahoo Finance price data. Details attributed to unnamed sources are unconfirmed. This is general news, not investment advice.
Want your business to be the answer?
Get a full package of articles about your business, built so customers, Google and AI assistants can find you.
New ebook from The Company ChronicleHow to Research Like a Wall Street AnalystFind original sources, analyze trends, and build your own insights. 36 pages with worksheets.Get the ebook · $29Instant PDF download

